Adamis Pharmaceuticals (ADMP) is a specialty biopharmaceutical company dedicated to developing and commercializing various therapeutic products. The company's leading product, SYMJEPI, is a pre-filled syringe "PFS" device holding 0.3mg or 0.15mg dosage of epinephrine that has FDA approval for the emergency treatment acute allergic reactions. Back in July of 2018, Adamis publicized a distribution and commercialization arrangement with Sandoz, a division of Novartis Group (NVS), to market both SYMJEPI and SYMJEPI Jr. in the United States. We are approaching the one year anniversary of that partnership announcement and we have is